Target intelligence / Profile preview

CEA cell adhesion molecule 20 (CEACAM20)

Target
CEACAM20
Molecular classification
Cell adhesion molecule, Immunoglobulin superfamily, Transmembrane protein
01

Overview

CEA cell adhesion molecule 20 (CEACAM20) is a transmembrane glycoprotein member of the immunoglobulin superfamily, primarily expressed on the apical plasma membrane of intestinal epithelial cells[2][3][7]. CEACAM20 possesses four extracellular Ig-like domains and contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic region[3]. Upon tyrosine phosphorylation, CEACAM20 binds to and activates spleen tyrosine kinase (SYK), leading to downstream activation of the NF-κB pathway and the subsequent production of pro-inflammatory cytokines such as CXCL8/IL-8 and IL-6[2][3][7]. It is a physiological substrate for the protein tyrosine phosphatase SAP-1, which regulates its phosphorylation status and hence the local immune response in the intestinal epithelium[3]. The detailed signaling roles and disease associations of CEACAM20 are still under investigation, but the CEACAM family as a whole is implicated in cancer biology, host-pathogen interaction, and immune modulation[1][5][6].

Other names
CEACAM20Cell adhesion molecule CEACAM20UNQ9366PRO34155GPAD9366CEA cell adhesion molecule 20Carcinoembryonic antigen-related cell adhesion molecule 20
02

Mechanism of action

Not targeted by specific drugs known to date; mechanisms described involve activation of SYK tyrosine kinase and downstream NF-κB signaling leading to inflammatory cytokine production[2][3][7]

03

Biological functions

Regulation of immune system process[2][3][7]Signal transduction, including activation of the NF-κB pathway[3][7]Promotion of cytokine production (IL-8/CXCL8, IL-6)[2][3][7]Inflammatory responseCell adhesion
04

Disease associations

Inflammatory bowel disease / Colitis (via intestinal immune modulation)[3]Cancer (role less characterized than other CEACAMs, but implicated broadly via family association)[1][5]Infection (serves as potential docking site for pathogens, inferred from CEACAM family)[1][6]
05

Safety considerations

Specific safety concerns or therapeutic challenges for targeting CEACAM20 are not documented, but general challenges for the CEACAM family (e.g., redundancy, expression in normal tissue) may apply[1][5]

Beyond the preview

Go deeper on CEA cell adhesion molecule 20 (CEACAM20).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CEA cell adhesion molecule 20 (CEACAM20).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call